Skip to main content

Table 3 Detection of individual high-risk HPV genotypes by CLART and LA in 125 women with ≥ CIN2

From: Comparison of analytical and clinical performance of CLART HPV2 genotyping assay to Linear Array and Hybrid Capture 2: a split-sample study

High-risk genotype Prevalence Agreement
CLART, N (%) LA, N (%) Relative prevalence CLART vs. LA (95% CI) CLART+/LA+ CLART+/LA- CLART-/LA+ CLART-/LA- Total agreement (95% CI) Positive agreement (95% CI)
16 55 (44%) 57 (46%) 0.96 (0.73-1.27) 55 (44%) 0 (0%) 2 (2%) 68 (54%) 98% (94-100) 96% (88-100)
18 18 (14%) 18 (14%) 1.00 (0.55-1.83) 18 (14%) 0 (0%) 0 (0%) 107 (86%) 100% (97-100) 100% (81-100)
31 30 (24%) 30 (24%) 1.00 (0.64-1.55) 30 (24%) 0 (0%) 0 (0%) 95 (76%) 100% (97-100) 100% (88-100)
33 21 (17%) 22 (18%) 0.95 (0.55-1.64) 21 (17%) 0 (0%) 1 (1%) 103 (82%) 99% (96-100) 95% (77-100)
35 7 (6%) 6 (5%) 1.17 (0.40-3.37) 6 (5%) 1 (1%) 0 (0%) 118 (94%) 99% (96-100) 86% (42-100)
39 4 (3%) 12 (10%) 0.33 (0.11-1.01) 4 (3%) 0 (0%) 8 (6%) 113 (90%) 94% (88-97) 33% (10-65)
45 6 (5%) 17 (14%) 0.35 (0.14-0.87) 6 (5%) 0 (0%) 11 (9%) 108 (86%) 91% (85-96) 35% (14-62)
51 15 (12%) 17 (14%) 0.88 (0.46-1.69) 15 (12%) 0 (0%) 2 (2%) 108 (86%) 98% (94-100) 88% (64-99)
52 17 (14%) 15 (12%) 1.13 (0.59-2.17) 11 (9%) 6 (5%) 4 (3%) 104 (83%) 92% (86-96) 52% (30-74)
56 6 (5%) 9 (7%) 0.67 (0.24-1.82) 5 (4%) 1 (1%) 4 (3%) 115 (92%) 96% (91-99) 50% (19-81)
58 19 (15%) 10 (8%) 1.90 (0.92-3.92) 10 (8%) 9 (7%) 0 (0%) 106 (85%) 93% (87-97) 53% (29-76)
59 9 (7%) 10 (8%) 0.90 (0.38-2.14) 8 (6%) 1 (1%) 2 (2%) 114 (91%) 98% (93-100) 73% (39-94)
68 7 (6%) 3 (2%) 2.33 (0.62-8.82) 0 (0%) 7 (6%) 3 (2%) 115 (92%) 92% (86-96) 0% (0-31)